Preclinical human and murine models of hepatocellular carcinoma (HCC)

被引:1
|
作者
Sundi, Pharidah Rajan Ibrahim Omar [1 ,2 ]
Thipe, Velaphi C. [3 ]
Omar, Mohamed Abdullahi [4 ]
Adelusi, Temitope Isaac [5 ]
Gedefa, Jalene [6 ]
Olaoba, Olamide T. [7 ]
机构
[1] Lusaka Apex Med Univ, Off Mumbwa Rd, Lusaka 10101, Zambia
[2] Pan African Org Hlth Educ & Res POHER, Ballwin, MO USA
[3] Univ Missouri, Inst Green Nanotechnol & Canc Nanotechnol, Dept Radiol, Columbia, MO 65211 USA
[4] Univ Nairobi, Fac Hlth Sci, Nairobi, Kenya
[5] Univ Missouri, Dept Surg, Columbia, MO 65211 USA
[6] Addis Ababa Univ, Coll Hlth Sci, Addis Ababa, Ethiopia
[7] Univ Missouri, Dept Mol Microbiol & Immunol, Columbia, MO 65211 USA
关键词
HCC; Preclinical murine model; Preclinical human model; Liver cancer; FLUORESCENCE-GUIDED SURGERY; CANCER LIVER METASTASIS; CELL-LINE; MOUSE MODELS; ALPHA-FETOPROTEIN; IN-VITRO; TUMOR; PROGNOSIS; SERUM; ACCUMULATION;
D O I
10.1016/j.clinre.2024.102418
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is the most frequent liver cancer, which account for more than 90 % of all liver cancer cases. It is the fifth leading cause of cancer globally and the second leading cause of cancer-related mortality in men. The availability of competent HCC preclinical models is fundamental to the success of mechanistic studies, molecular target identification, and drug testing. However, there are challenges associated with the use of these models. In this review, we provided updates on various cell lines, animals, and human HCC models, their specific preclinic use and associated potential challenges. Overall, the understanding of the merits and demerits of a particular HCC model will improve model selection for various preclinical studies.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Human Hepatocellular Carcinoma (HCC)
    Buonaguro, Luigi
    [J]. CANCERS, 2020, 12 (12)
  • [2] Antitumor activity of lenvatinib mesilate in human hepatocellular carcinoma preclinical models
    Matsuki, Masahiro
    Yamamoto, Yuji
    Hoshi, Taisuke
    Kimura, Takayuki
    Funahashi, Yasuhiro
    Matsui, Junji
    [J]. CANCER RESEARCH, 2017, 77
  • [3] The hepatocellular carcinoma (HCC)
    Zendeh, D
    Holle, A
    Liebe, S
    [J]. MEDIZINISCHE WELT, 1998, 49 (10): : 489 - 498
  • [4] HEPATOCELLULAR CARCINOMA (HCC)
    Villanueva, A.
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [5] ONCOGENES IN HUMAN AND DUCK HEPATOCELLULAR-CARCINOMA (HCC)
    GU, JR
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1987, : 8 - 8
  • [6] CATALASE ACTIVITY IN HUMAN HEPATOCELLULAR-CARCINOMA (HCC)
    BELLISOLA, G
    CASARIL, M
    GABRIELLI, GB
    CARAFFI, M
    CORROCHER, R
    [J]. CLINICAL BIOCHEMISTRY, 1987, 20 (06) : 415 - 417
  • [7] VEGF and iNOS expression in human hepatocellular carcinoma (HCC)
    Boix, L
    Armengol, C
    Solé, M
    Jiménez, W
    Llovet, JM
    Rodés, J
    Bruix, J
    [J]. JOURNAL OF HEPATOLOGY, 2001, 34 : 106 - 106
  • [8] Preclinical mouse models of hepatocellular carcinoma: An overview and update
    Gu, Catherine Yujia
    Lee, Terence Kin Wah
    [J]. EXPERIMENTAL CELL RESEARCH, 2022, 412 (02)
  • [9] Experimental Models of Hepatocellular Carcinoma-A Preclinical Perspective
    Blidisel, Alexandru
    Marcovici, Iasmina
    Coricovac, Dorina
    Hut, Florin
    Dehelean, Cristina Adriana
    Cretu, Octavian Marius
    [J]. CANCERS, 2021, 13 (15)
  • [10] FIBRONECTIN IN HUMAN HEPATOCELLULAR-CARCINOMA (HCC) AND HCC CELL-LINES
    TSUMAGARI, J
    [J]. ACTA PATHOLOGICA JAPONICA, 1987, 37 (03): : 413 - 423